Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: A prospective, observational, noninterventional study

Table 2 Baseline characteristics, N = 2339

Age (years)*
Mean ± SD	65.5 ± 11.7
Range	10, 96
Male gender, n (%)*	1047 (44.8)
Primary diagnosis^†
Open-angle glaucoma	1910
Ocular hypertension	177
Pseudoexfoliation glaucoma	114
Normal-tension glaucoma	111
Glaucoma NOS	41
Angle-closure glaucoma	17
Pigmentary glaucoma	12
Ocular hypotensive therapy reported by ≥50 subjects
Bimatoprost	50
Brinzolamide	92
Dorzolamide/timolol FC	92
Latanoprost	343
Timolol	173
Timolol maleate	115
Travoprost	93
Reason(s) for switching to latanoprost/timolol FC,^‡ n (%)
Inadequate IOP reduction on prior therapy	1830 (78.2)
Desire to simplify treatment with once-daily dosing	687 (29.4)
Side effects/hypersensitivity reactions with prior therapy	219 (9.4)
Prior therapy contraindicated due to subject's signs/symptoms	103 (4.4)
Other	120 (5.1)

FC = fixed combination; IOP = intraocular pressure; NOS = not otherwise specified; SD = standard deviation.
*Age was missing for 57 subjects; gender was missing for 48 subjects.
^†Counts are based on diagnoses for both eyes. If a subject had a different diagnosis for each eye, these were counted twice, and if a subject had more than one diagnosis for the same eye, each was counted.
^‡More than one reason could have been recorded by physicians. Percentages are based on the number of patients (N = 2339).

ISSN: 1471-2415